Dr. David J. Drutz, former CEO of Inspire Pharmaceuticals and former chairman of Tranzyme Pharma (NASDAQ: TZYM), will chair the Gentris Corp. board of directors, Gentris announced.

Gentris focuses on applying genomic biomarkers to clinical studies and has supported more than 500 clinical trials.

Drutz, whose career has covered medicine, pharmaceuticals, biotechnology, and venture capital, joined the Gentris Board a year ago, the company said Wednesday.

Gentris also said Tim Gupton, a partner in the Hughes, Pittman & Gupton accounting firm and biopharma entrepreneur, has  become a board member.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.